WALTHAM, Mass.–(BUSINESS WIRE)–#autism–Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that management will participate in a fireside chat at The JMP Securities CNS Forum on Wednesday, August 19, 2020 at 2:00 PM ET.
About Axial Biotherapeutics
Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.
Contacts
Investor:
David H Donabedian
781-701-8468
david@axialbiotherapeuics.com